Biosimilars
Most recent (1)

Biosimilars in the U.S.: More Approvals But Not More Access

Biosimilars have the potential to significantly reduce treatment costs. We take a look at the growing biosimilar pathway.

Read More
The Capital Building in Washington D.C.